Heartburn: When to See a Doctor

What Causes Heartburn in the First Place

Heartburn results from gastric acid contacting the esophageal mucosa when the lower esophageal sphincter (LES) relaxes inappropriately or fails to maintain adequate pressure. The burning sensation behind the sternum is not actually cardiac pain, though the two can be difficult to distinguish clinically.

The LES normally maintains a resting pressure of 10-30 mmHg above intragastric pressure. Transient lower esophageal sphincter relaxations (TLESRs) account for up to 70% of reflux episodes in patients without a hiatal hernia, according to data from ambulatory pH monitoring studies 1. These relaxations occur independently of swallowing and allow gastric contents to move retrograde.

Common contributors include obesity (particularly central adiposity, which increases intra-abdominal pressure by 2-10 mmHg), hiatal hernia (present in 50-94% of patients with severe erosive esophagitis), pregnancy, smoking, alcohol, and certain medications such as calcium channel blockers, anticholinergics, and NSAIDs 2. Dietary triggers vary between individuals but frequently include coffee, chocolate, fatty foods, citrus, tomato-based products, and peppermint.

A 2020 prospective cohort study (N=42,955) in the BMJ found that adherence to five lifestyle factors (normal weight, never smoking, moderate physical activity, limited coffee/tea/soda, and a prudent diet) was associated with a 37% reduction in GERD symptom risk compared with adherence to none 3.

The Twice-a-Week Rule: When Frequency Signals Disease

Occasional heartburn after a large meal is common and rarely dangerous. The line between physiologic reflux and gastroesophageal reflux disease (GERD) is frequency and impact on quality of life. The American College of Gastroenterology (ACG) defines GERD as troublesome symptoms or complications caused by reflux of stomach contents, with twice-weekly occurrence serving as the clinical threshold for suspecting the diagnosis 4.

This matters because chronic acid exposure changes esophageal tissue. The 2022 ACG Clinical Guideline on GERD states: "Patients with typical GERD symptoms who respond to an empiric PPI trial do not require endoscopy unless alarm features are present" 4. That empiric trial lasts 8 weeks. If symptoms persist or recur after stopping, the diagnosis needs confirmation and the management plan needs escalation.

The Montreal Classification, endorsed by 44 international experts and published in the American Journal of Gastroenterology, formally separated GERD into esophageal syndromes (typical reflux, reflux chest pain, erosive esophagitis, stricture, Barrett esophagus, adenocarcinoma) and extra-esophageal syndromes (reflux cough, laryngitis, asthma, dental erosions) 5. This classification helps clinicians determine which patients need referral beyond primary care.

Red-Flag Symptoms That Demand Urgent Evaluation

Certain symptoms alongside heartburn indicate possible complications or alternative diagnoses that require immediate medical attention. These alarm features mandate endoscopic evaluation rather than empiric treatment.

Dysphagia (difficulty swallowing) affects roughly 30% of GERD patients at some point, but progressive solid-food dysphagia suggests a peptic stricture, eosinophilic esophagitis, or malignancy. The ACG guidelines recommend upper endoscopy for any patient presenting with dysphagia regardless of age or symptom duration 4.

Odynophagia (painful swallowing) points toward esophageal ulceration or pill esophagitis. Unintentional weight loss exceeding 5% of body weight over 6-12 months in the setting of reflux symptoms raises suspicion for esophageal or gastric malignancy. Hematemesis (vomiting blood) or melena (black tarry stools) indicates gastrointestinal bleeding requiring urgent evaluation.

Chest pain mimicking cardiac disease deserves particular attention. A systematic review in the Annals of Internal Medicine found that up to 50% of patients with non-cardiac chest pain have GERD as the underlying cause 6. The critical first step is excluding cardiac pathology. Any chest pain with exertion, radiation to the arm or jaw, or associated shortness of breath needs cardiac evaluation before attributing symptoms to reflux.

New-onset symptoms after age 50, persistent vomiting, a palpable abdominal mass, iron-deficiency anemia, or a family history of upper GI malignancy also warrant prompt investigation. The combination of male sex, age over 50, chronic reflux exceeding 5 years, obesity, and tobacco use identifies a population at highest risk for Barrett esophagus and esophageal adenocarcinoma 7.

How Heartburn Is Diagnosed

The diagnostic approach depends on symptom severity, duration, and the presence of alarm features. Most patients with typical symptoms (heartburn and regurgitation) receive an empiric PPI trial as both a therapeutic and diagnostic maneuver. Symptom response to a PPI has roughly 78% sensitivity and 54% specificity for GERD 8.

Upper endoscopy (EGD) allows direct visualization and biopsy of the esophageal mucosa. The Los Angeles classification grades erosive esophagitis from A (one or more mucosal breaks <5 mm) to D (circumferential mucosal breaks). However, up to 70% of patients with GERD symptoms have a normal endoscopy (non-erosive reflux disease, or NERD) 9.

Ambulatory pH monitoring (either wireless Bravo capsule or catheter-based) provides objective measurement of esophageal acid exposure over 24-96 hours. An acid exposure time (AET) exceeding 6% is conclusively abnormal, while AET below 4% is physiologic 4. This test is most valuable in PPI non-responders and before anti-reflux surgery.

High-resolution esophageal manometry evaluates LES pressure and esophageal peristalsis. It does not diagnose GERD directly but identifies motility disorders that mimic or coexist with reflux and is mandatory before surgical fundoplication to rule out achalasia or absent peristalsis.

Impedance monitoring combined with pH testing detects both acid and non-acid reflux events, which is particularly useful in patients with persistent symptoms on PPI therapy who may have weakly acidic or gaseous reflux 10.

Barrett Esophagus: The Complication That Changes Everything

Barrett esophagus (BE) develops when chronic acid exposure replaces the normal squamous epithelium of the distal esophagus with specialized intestinal metaplasia (goblet cells). This represents a premalignant condition. A meta-analysis published in Gastroenterology estimated that BE affects 5.6% of the general population undergoing endoscopy for any indication 11.

The annual progression rate from non-dysplastic BE to esophageal adenocarcinoma is approximately 0.3-0.5% per year, based on large registry studies from Denmark and Northern Ireland 12. With low-grade dysplasia, that rate increases to 0.5-0.7% annually. High-grade dysplasia carries a 5-8% annual progression risk, prompting intervention.

The ACG recommends screening endoscopy for BE in patients with chronic GERD symptoms (over 5 years) who have at least three additional risk factors: male sex, age over 50, White race, central obesity, current or former smoking, or family history of BE or esophageal adenocarcinoma 7. Surveillance intervals depend on the presence and grade of dysplasia, ranging from every 3-5 years for non-dysplastic BE to every 3 months for confirmed high-grade dysplasia not treated with ablation.

Radiofrequency ablation (RFA) has transformed the management of dysplastic BE. The AIM Dysplasia Trial (N=127) demonstrated complete eradication of dysplasia in 90.5% of patients and complete eradication of intestinal metaplasia in 77.4% at 12 months 13.

Evidence-Based Treatment Options

Treatment follows a stepwise approach: lifestyle modification first, then pharmacotherapy, then procedural intervention for refractory cases.

Lifestyle modifications with the strongest evidence include weight loss in overweight/obese patients (a prospective study showed that a BMI reduction of 3.5 units or greater was associated with a 40% reduction in GERD symptom frequency 3), head-of-bed elevation by 6-8 inches, avoidance of meals within 2-3 hours of lying down, and cessation of smoking.

Proton pump inhibitors remain the cornerstone pharmacotherapy. A Cochrane systematic review of 134 trials (N=35,978) found PPIs superior to H2-receptor antagonists for healing erosive esophagitis (relative risk of healing: 0.24 favoring PPIs over placebo at 8 weeks) 14. Standard-dose PPIs (omeprazole 20 mg, lansoprazole 30 mg, esomeprazole 20 mg, pantoprazole 40 mg, rabeprazole 20 mg) are taken 30-60 minutes before the first meal of the day.

H2-receptor antagonists (famotidine 20-40 mg) serve as add-on therapy for nocturnal acid breakthrough or as step-down therapy after PPI-induced healing. Alginate-antacid combinations (such as sodium alginate/potassium bicarbonate) form a mechanical raft on the gastric pool that physically blocks reflux and may be particularly useful for postprandial symptoms.

Potassium-competitive acid blockers represent a newer class. Vonoprazan, approved by the FDA in November 2023, achieves faster and more sustained acid suppression than PPIs because it does not require acid activation and has a longer half-life at the proton pump. Phase 3 trials demonstrated non-inferiority to lansoprazole for healing erosive esophagitis with potentially faster symptom relief 15.

When Surgery Becomes the Right Answer

Anti-reflux surgery is appropriate for patients with objectively confirmed GERD (positive pH study) who cannot tolerate long-term PPI therapy, prefer not to take lifelong medication, or have large-volume regurgitation that PPIs cannot control. Laparoscopic Nissen fundoplication (360-degree wrap) remains the most studied procedure.

The LOTUS trial, a 5-year multicenter randomized controlled trial (N=554) comparing laparoscopic fundoplication to esomeprazole in chronic GERD, found similar remission rates at 5 years (92% surgery vs. 88% medical therapy, p=0.048), though surgical patients had more dysphagia and flatulence 16. Symptom recurrence requiring reoperation occurs in 3-6% of patients within 10 years.

Magnetic sphincter augmentation (LINX device) offers a less invasive alternative. The device consists of titanium beads with magnetic cores placed around the LES. A 5-year prospective study (N=100) showed that 85% of patients achieved at least 50% reduction in PPI use, with normalized esophageal acid exposure in 64% 17. The procedure preserves the ability to belch and vomit, unlike a tight fundoplication.

Transoral incisionless fundoplication (TIF) using the EsophyX device creates a 2-3 cm full-thickness serosa-to-serosa fundoplication endoscopically. A sham-controlled trial (RESPECT, N=129) showed significant improvement in troublesome regurgitation (67% vs. 45%, p=0.023) and reduction in PPI use at 6 months 18.

Long-Term PPI Safety: Separating Signal From Noise

Concerns about chronic PPI use populate both medical literature and patient anxiety. The evidence deserves honest assessment. Observational studies have reported statistical associations between long-term PPI use and fractures, chronic kidney disease, C. difficile infection, hypomagnesemia, B12 deficiency, dementia, and gastric fundic gland polyps 19.

The COMPASS trial (N=17,598), a large randomized controlled trial, compared pantoprazole 40 mg daily to placebo over 3 years. It found no significant increase in pneumonia, fracture, chronic kidney disease, dementia, or cardiovascular events 20. The only confirmed associations were a modest increase in enteric infections (HR 1.33) and a small increase in fundic gland polyps (benign).

The ACG position: "The benefits of PPIs outweigh potential risks in most patients with documented acid-related conditions." Patients should take the lowest effective dose for the shortest necessary duration. Annual reassessment of PPI necessity is appropriate. For patients on indefinite therapy (confirmed Barrett esophagus, severe erosive esophagitis Los Angeles C/D, or post-anti-reflux surgery for incomplete repair), the risk-benefit ratio clearly favors continuation.

Heartburn vs. Heart Attack: A Distinction That Saves Lives

The overlap between cardiac and esophageal pain is not trivial. Both the heart and esophagus share visceral afferent innervation through the vagus nerve and thoracic sympathetic chain. A study in the American Journal of Gastroenterology found that among patients presenting to emergency departments with chest pain, 23% had GERD as the final diagnosis after cardiac causes were excluded 6.

Features suggesting cardiac origin: exertional onset, pressure or squeezing quality, radiation to left arm/jaw/back, associated diaphoresis or dyspnea, relief with nitroglycerin (though esophageal spasm may also respond to nitroglycerin). Features suggesting esophageal origin: burning quality, postprandial timing, relief with antacids, associated regurgitation or water brash, reproduction by palpation of the epigastrium.

No clinical feature reliably distinguishes the two. The safe approach: any patient over 40 with new chest pain, any patient with cardiovascular risk factors, or any patient with concerning associated symptoms should have cardiac causes excluded first. ECG, troponin, and clinical assessment precede GI workup. A negative cardiac evaluation does not automatically confirm GERD. Proper esophageal testing establishes the diagnosis.

Special Populations Requiring Different Approaches

Pregnancy: Heartburn affects 40-85% of pregnant women, with highest prevalence in the third trimester due to progesterone-mediated LES relaxation and mechanical compression from the gravid uterus. Calcium carbonate antacids are first-line. Ranitidine was withdrawn globally in 2020 due to NDMA contamination concerns; famotidine has replaced it as the H2RA of choice. PPIs (omeprazole, lansoprazole) are category B and appropriate when antacids fail 21.

Elderly patients: New-onset reflux symptoms after age 60 require endoscopy rather than empiric PPI therapy due to increased malignancy risk. Decreased esophageal peristaltic amplitude with aging impairs acid clearance. PPI interactions with clopidogrel (attenuated antiplatelet effect with omeprazole, less so with pantoprazole) require attention in this population 22.

Patients on GLP-1 receptor agonists: Semaglutide and tirzepatide delay gastric emptying, which may paradoxically worsen or improve GERD depending on the mechanism. Delayed emptying increases gastric volume and distension (pro-reflux) but may reduce postprandial acid production. Patients starting GLP-1 therapy who notice new or worsening heartburn should report symptoms rather than assume the medication is protective. Pre-procedural guidance from the American Society of Anesthesiologists recommends holding GLP-1 agonists before elective endoscopy to reduce aspiration risk 23.